Search

Your search keyword '"Sperr, Wolfgang R"' showing total 1,531 results

Search Constraints

Start Over You searched for: Author "Sperr, Wolfgang R" Remove constraint Author: "Sperr, Wolfgang R"
1,531 results on '"Sperr, Wolfgang R"'

Search Results

51. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome

52. Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils

55. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

56. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

57. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

58. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

59. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

61. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research

62. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

63. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis

64. Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

65. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

66. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

71. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

72. Vienna Cancer Stem Cell Club (VCSCC): 20 year jubilee and future perspectives

73. Time-dependent changes in mortality and transformation risk in MDS

75. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology

76. Mast cell leukemia:clinical and molecular features and survival outcomes of patients in the ECNM Registry

77. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.

78. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

79. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

80. Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

81. Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

82. Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

83. Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

84. Supplementary Data from Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

88. Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V(+) systemic mastocytosis: a preclinical study

90. Supplemental Table S3 from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future

91. Supplementary Table 6 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

92. Supplementary Table 7 - 8 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

93. Data from Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

94. Supplementary Methods, Supplementary Tables 1-5, Supplementary Figures 1-11, Supplementary References from Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

95. Supplementary Figure 2 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

96. Data from Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future

97. Supplementary Table 5 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

98. Supplementary Figure 3 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

99. Supplementary Tables 1 - 4 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

100. Supplementary Figure 1 from Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

Catalog

Books, media, physical & digital resources